Free Trial

Wall Street Zen Downgrades ReposiTrak (NYSE:TRAK) to Hold

ReposiTrak logo with Computer and Technology background

Key Points

  • Wall Street Zen has downgraded ReposiTrak from a "buy" rating to a "hold" rating, with Weiss Ratings also maintaining a "hold" rating.
  • Shares of ReposiTrak traded down $0.55, reaching $14.91, with a one-year range between $13.86 and $25.01.
  • Insider trading activity includes CEO Randall K. Fields selling 4,700 shares, contributing to a 7.56% decrease in his stake in the company.
  • Five stocks we like better than ReposiTrak.

ReposiTrak (NYSE:TRAK - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Friday.

Separately, Weiss Ratings reiterated a "hold (c+)" rating on shares of ReposiTrak in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of "Hold".

Read Our Latest Research Report on ReposiTrak

ReposiTrak Price Performance

Shares of NYSE TRAK traded down $0.55 during midday trading on Friday, reaching $14.91. 84,847 shares of the stock traded hands, compared to its average volume of 60,364. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $272.55 million, a PE ratio of 42.60 and a beta of 0.44. ReposiTrak has a one year low of $13.86 and a one year high of $25.01. The stock has a 50 day moving average of $16.63.

ReposiTrak (NYSE:TRAK - Get Free Report) last posted its earnings results on Monday, September 29th. The company reported $0.09 EPS for the quarter. The firm had revenue of $5.76 million during the quarter. ReposiTrak had a return on equity of 14.35% and a net margin of 30.55%.

Insiders Place Their Bets

In related news, CEO Randall K. Fields sold 4,700 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $15.71, for a total transaction of $73,837.00. Following the sale, the chief executive officer owned 57,500 shares in the company, valued at approximately $903,325. This represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 88,500 shares of company stock worth $1,519,974. Corporate insiders own 44.00% of the company's stock.

Institutional Trading of ReposiTrak

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in ReposiTrak by 63.5% in the second quarter. BNP Paribas Financial Markets now owns 1,633 shares of the company's stock worth $32,000 after purchasing an additional 634 shares during the period. Tower Research Capital LLC TRC increased its stake in ReposiTrak by 397.3% in the second quarter. Tower Research Capital LLC TRC now owns 3,620 shares of the company's stock worth $71,000 after purchasing an additional 2,892 shares during the period. R Squared Ltd purchased a new stake in ReposiTrak in the second quarter worth $235,000. Rhumbline Advisers increased its stake in ReposiTrak by 69.1% in the second quarter. Rhumbline Advisers now owns 18,036 shares of the company's stock worth $354,000 after purchasing an additional 7,371 shares during the period. Finally, Coldstream Capital Management Inc. increased its stake in ReposiTrak by 47,619.0% in the second quarter. Coldstream Capital Management Inc. now owns 20,042 shares of the company's stock worth $394,000 after purchasing an additional 20,000 shares during the period. Hedge funds and other institutional investors own 27.35% of the company's stock.

ReposiTrak Company Profile

(Get Free Report)

Park City Group, Inc, a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance and Food Safety solutions, which reduces potential regulatory and legal risk from their supply chain partners; and ReposiTrak Supply Chain solutions that enables customers to manage relationships with suppliers.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ReposiTrak Right Now?

Before you consider ReposiTrak, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ReposiTrak wasn't on the list.

While ReposiTrak currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.